ClinicalTrials.gg
CompletedNCT07076056Updated Jul 21, 2025

Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2

A Phase 3 interventional study of DW1026C1 and DW1026C2 in Type 2 Diabetes, sponsored by Daewon Pharmaceutical Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-07-21.

Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Oct 2022, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
19 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of — 70 open to participants now, 84 under way, 26 of them phase 3. Diabetes Mellitus, Type 2 · Korea, Republic of.

Enrollment
210th of 493
230 · median 174
Started
2022
with 24 others
Phase 3
200 of 571
22 open now
Registered
526th of 571
by date

Among the 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, this one is the 210th largest by enrollment of the 493 interventional ones that give a count, is one of 25 that started in 2022, is one of 200 in phase 3, and was the 526th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

70 of the 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 373 (42%) set no upper age limit and 384 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 Add-on to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sitagliptin Combination Therapy

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
19 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are diagnosed with Type2 Diabetes
  • 19 ≤ Age ≤ 85
  • 7.0% ≤ ≤ 10.5%

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of acute pancreatitis
  • Patients with a history of pre-diabetic coma
  • Patients with a history of diagnosis of malignant tumors within 5 years prior to visit 1
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
230 participants (actual)

Study arms

  • Experimental
    DW1026C1 & DW1026C2 placebo & DW1026S placebo

    Drug: DW1026C1

  • Experimental
    DW1026C1 placebo & DW1026C2 & DW1026S placebo

    Drug: DW1026C2

  • Placebo comparator
    DW1026C1 placebo & DW1026C2 placebo & DW1026S

    Drug: DW1026S

Interventions

  • DrugDW1026C1

    Sitagliptin 100mg+Empagliflozin 10mg

  • DrugDW1026C2

    Sitagliptin 100mg+Empagliflozin 25mg

  • DrugDW1026S

    Sitagliptin 100mg

06

What researchers measure

Primary outcomes

  1. % change of HbA1c

    % change of HbA1c in week 24 from baseline

    Time frame: 24 weeks

07

Study locations

1 site
  • Yeouido St. Mary's Hospital The Catholic University
    Seoul, South Korea
08

References and documents

Publications

  • Lim S, Kim TN, Mok JO, Chung CH, Hwang YC, Cho HC, Won JC, Jeon E, Kang ES, Lee KY, Kim CH, Kwak SH, Park CY, Park KS, Kim SY, Lee JH, Lee SH, Cho DH, Kwon HS, Han KA. Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial. Diabetes Obes Metab. 2026 Jun;28(6):4847-4859. doi: 10.1111/dom.70669. Epub 2026 Mar 26. PubMed 41883295 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Dec 2023, 13 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2025
First posted
Jul 21, 2025
StartActual
Oct 27, 2022
Primary completionActual
Dec 4, 2023
CompletionActual
Jun 19, 2024
Last update
Jul 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07076056
Responsible party
Sponsor
First posted
Jul 21, 2025
Start date
Oct 27, 2022
Primary completion
Dec 4, 2023
Completion
Jun 19, 2024
Last update
Jul 21, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion